OraSure Technologies (NASDAQ:OSUR) CFO Acquires $94,639.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth Mcgrath purchased 32,300 shares of the stock in a transaction dated Friday, March 20th. The shares were acquired at an average cost of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the acquisition, the chief financial officer directly owned 589,562 shares of the company’s stock, valued at approximately $1,727,416.66. This trade represents a 5.80% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

OraSure Technologies Stock Up 2.6%

Shares of NASDAQ OSUR opened at $3.14 on Thursday. The stock has a market cap of $217.07 million, a P/E ratio of -3.38 and a beta of 0.88. The firm’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $2.79. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. The company had revenue of $26.76 million for the quarter, compared to analyst estimates of $26.44 million. On average, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Kotler Kevin acquired a new position in shares of OraSure Technologies in the 4th quarter valued at $4,359,000. Altai Capital Management L.P. raised its holdings in OraSure Technologies by 73.4% during the 3rd quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock worth $12,034,000 after buying an additional 1,586,488 shares during the period. Millennium Management LLC lifted its stake in OraSure Technologies by 71.1% during the third quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock valued at $6,781,000 after buying an additional 878,151 shares in the last quarter. Systematic Financial Management LP lifted its stake in OraSure Technologies by 35.3% during the second quarter. Systematic Financial Management LP now owns 2,229,076 shares of the medical instruments supplier’s stock valued at $6,687,000 after buying an additional 581,926 shares in the last quarter. Finally, Archon Capital Management LLC acquired a new position in shares of OraSure Technologies in the fourth quarter worth about $1,388,000. 93.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, OraSure Technologies currently has a consensus rating of “Reduce” and a consensus target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.